Xenon Pharmaceuticals IncNASDAQ:XENE
- LAST PRICE37.7600
- TODAY'S CHANGE (%)-0.0700 (-0.1850%)
- Bid / Lots37.6700/ 2
- Ask / Lots37.9000/ 4
- Open / Previous Close37.4900 / 37.8300
- Day Range
- 52 Week Range
- Volume147,827
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XENE |
|---|---|---|
| 09:32 ET | 743 | 37.49 |
| 09:34 ET | 100 | 37.57 |
| 09:36 ET | 700 | 37.53 |
| 09:38 ET | 200 | 37.5 |
| 09:45 ET | 400 | 37.4633 |
| 09:48 ET | 100 | 37.47 |
| 10:01 ET | 100 | 37.67 |
| 10:10 ET | 100 | 37.67 |
| 10:15 ET | 400 | 37.79 |
| 10:17 ET | 100200 | 37.73 |
| 10:19 ET | 400 | 37.74 |
| 10:21 ET | 173 | 37.721 |
| 10:24 ET | 100 | 37.83 |
| 10:26 ET | 300 | 37.795 |
| 10:32 ET | 500 | 38.13 |
| 10:33 ET | 400 | 38.03 |
| 10:35 ET | 200 | 38.1 |
| 10:46 ET | 483 | 38.003 |
| 10:48 ET | 729 | 38.17 |
| 10:55 ET | 736 | 38.15 |
| 11:00 ET | 100 | 38.01 |
| 11:02 ET | 300 | 38.01 |
| 11:04 ET | 100 | 38.02 |
| 11:08 ET | 100 | 38.045 |
| 11:15 ET | 146 | 38.01 |
| 11:20 ET | 1158 | 37.98 |
| 11:22 ET | 100 | 37.985 |
| 11:24 ET | 200 | 38.04 |
| 11:29 ET | 525 | 38.1 |
| 11:31 ET | 291 | 38.002 |
| 11:33 ET | 100 | 38.075 |
| 11:38 ET | 100 | 38.085 |
| 11:40 ET | 224 | 38.04 |
| 11:44 ET | 100 | 38.115 |
| 11:45 ET | 100 | 38.192 |
| 11:51 ET | 1728 | 38.2 |
| 11:54 ET | 100 | 38.28 |
| 11:56 ET | 700 | 38.115 |
| 12:00 ET | 100 | 38.08 |
| 12:02 ET | 200 | 38.11 |
| 12:07 ET | 300 | 38.06 |
| 12:09 ET | 5036 | 38.05 |
| 12:12 ET | 572 | 38.01 |
| 12:16 ET | 100 | 38.04 |
| 12:18 ET | 4443 | 38.04 |
| 12:20 ET | 336 | 38.01 |
| 12:21 ET | 7233 | 37.85 |
| 12:25 ET | 300 | 37.84 |
| 12:27 ET | 100 | 37.83 |
| 12:30 ET | 300 | 37.84 |
| 12:32 ET | 100 | 37.89 |
| 12:38 ET | 400 | 37.76 |
Jun 5, 2024
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference, from 4:01PM ET on Wednesday Jun 05, 2024 by Dow Jones
4:01PM ET on Wednesday Jun 05, 2024 by Dow Jones
May 28, 2024
May 10, 2024
DJ Xenon Pharmaceuticals Is Maintained at Buy by Needham, from 6:12PM ET on Friday May 10, 2024 by Dow Jones
6:12PM ET on Friday May 10, 2024 by Dow JonesDJ Xenon Pharmaceuticals Is Maintained at Buy by Citigroup, from 5:48PM ET on Friday May 10, 2024 by Dow Jones
5:48PM ET on Friday May 10, 2024 by Dow JonesDJ Xenon Pharmaceuticals Is Maintained at Outperform by Wedbush, from 9:30AM ET on Friday May 10, 2024 by Dow Jones
9:30AM ET on Friday May 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xenon Pharmaceuticals Inc | 2.9B | -13.9x | --- |
Janux Therapeutics Inc | 2.8B | -35.3x | --- |
Apogee Therapeutics Inc | 2.7B | -20.1x | --- |
Biohaven Ltd | 3.1B | -5.0x | --- |
SpringWorks Therapeutics Inc | 3.1B | -7.8x | --- |
Dyne Therapeutics Inc | 3.1B | -7.9x | --- |
Company Information
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Contact Information
- Headquarters
- 3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
- Phone
- 604-484-3300
- Fax
- 604-484-3450
Executives
- Chairman of the Board
- Simon Pimstone
- President, Chief Executive Officer, Director
- Ian Mortimer
- Chief Financial Officer
- Sherry Aulin
- Executive Vice President - Drug Discovery
- James Empfield
- Executive Vice President - Strategy and Innovation
- Robin Sherrington
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.9B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.22 |
EPS | $-2.71 |
Book Value | $12.31 |
P/E Ratio | -13.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
